Dermot McGovern M.D.

Dermot McGovern MD, PhD, FRCP(Lon), FACG has an extensive work experience in the field of medicine and research. Dermot started their career at the University of Oxford, where they conducted genetic research in inflammatory bowel diseases, leading to the award of their PhD. In 2007, they joined Cedars-Sinai as the Director of Translational Medicine and later became the Director of Precision Health. Dermot also served as the Co-Director of the Inflammation Core for the PhD Program in Translational Medicine and the Lead for Personalized Medicine in IBD. In 2017, they co-founded Prometheus Biosciences, Inc., a biotech company focused on developing therapies for inflammatory bowel disease and other immune-mediated diseases. Dermot McGovern has made significant contributions to precision medicine and translational research throughout their career.

Dermot McGovern MD, PhD, FRCP(Lon), FACG, AGAF obtained a Bachelor of Medicine and Bachelor of Surgery (MB BS) degree in Medicine from St Mary's Hospital Medical School, London, from 1983 to 1988. Dermot pursued further studies at the University of Oxford, where they completed a Doctor of Philosophy (PhD) in Complex Disease genetics from 2000 to 2005. Prior to their medical education, Dermot attended Hurstpierpoint College in Sussex, UK.